

DIASORIN LAUNCHES THE ALDOSTERONE ASSAY ON ITS LIAISON PLATFORMS, FOR OUTSIDE THE US AND CANADA ONLY

January 28, 2013 - Saluggia (VC) - **DiaSorin** (FTSE MIB:DIA) is pleased to announce the **launch of the Aldosterone assay on its Liaison analyzers family, for outside the US and Canada only.**

The Aldosterone assay uses chemiluminescent immunoassay technology (CLIA) and is intended for the quantitative determination of Aldosterone in human serum, EDTA plasma and urine samples.

Aldosterone measurements are intended for use in the diagnosis and treatment of primary aldosteronism (*a disorder caused by excessive secretion of aldosterone by the adrenal gland*), hypertension caused by primary aldosteronism, selective hypoaldosteronism, edematous states and other conditions of electrolyte imbalance.

The addition of the new Aldosterone assay to the Liaison analyzer menu, will provide our customers with the opportunity to **complete the “Hypertension panel”**, comprising Direct Renin, which is already in use on more than 400 Liaison instruments. DiaSorin offers today **the broadest Endocrinology menu on a single fully automated system.**

1 billion people worldwide have high blood pressure, and this number is expected to increase to 1.56 billion people by the year 2025. This translates to around **1 out of 4 adults being afflicted by hypertension.**

Hypertension is prevalent in developing as well as in developed countries. Prolonged uncontrolled or inadequate treatment of hypertension is a major risk factor for the occurrence of heart attack, stroke, kidney failure and other cardiovascular diseases.

Aldosterone and renin tests are usually requested by clinicians together when a patient shows high blood pressure and low potassium. Even if potassium is normal, testing may be done if typical medications do not control the high blood pressure or if hypertension develops at an early age. Primary aldosteronism is a potentially curable form of hypertension, early detection and treatment are important to avoid complications. Aldosterone tests are also requested, amongst others, for patients suspected of adrenal insufficiency.

With the launch of Liaison Aldosterone, DiaSorin is set to be a key player in the Hypertension testing market for the years to come.

REFERENCE TABLE FOR DIASORIN PRODUCTS

Assay name	Aldosterone			
Diagnosis	Hypertension			
Potential market	1 bn people			
Business segment	Immunodiagnosics	✓	Molecular Diagnostics	
Technology	CLIA	✓	Extraction	
	ELISA		Amplification/Detection	
	RIA		HLA Typing	
Clinical Area	Infectious Disease		Infectious Disease	
	Hepatitis and Retroviruses			
	Oncology & Endocrinology	✓	Onco-hematology	
	Bone & Mineral			
	Cardiac Markers			
	GI Stool Testing			

Mr. Carlo Rosa, Chief Executive Officer of DiaSorin Group, commented *“I’m really proud to announce the launch of the Aldosterone assay on our Liaison analyzer family. The hypertension market is increasing consistently, and DiaSorin today is able to provide both the Aldosterone and the Renin tests on its Liaison platforms, allowing physicians to detect and treat the patients suffering with this disease, avoiding potential complications.*

The launch of the Aldosterone test on CLIA technology proves once again that DiaSorin is an innovating company able to successfully address product development challenges and offer new unique assays to our customers”.

For additional information, please contact:

Riccardo Fava
 External Relations Director - Head of IR and Media
 Tel: +39.0161.487988
riccardo.fava@diasorin.it

Margherita Sacerdoti
 Investor Relations Specialist
 Tel: +39.0161.487456
margherita.sacerdoti@diasorin.it